HeartBeam is a patient-centered health company that strives to alleviate impact of heart disease and protect cardiac patients by combining a novel ECG approach and artificial intelligence (AI) .

Heart Diagnosis Anywhere, Anytime


By Mary Alison

HeartBeam has embarked on solving a problem that is tremendously important—heart attack. It’s innovative, revolutionary product. .

"I wanted to build a 12 lead ECG that fits in your wallet," says Branislav Vajdić, PhD CEO and Founder of HeartBeam. A chip-designer from Intel, who had no baggage of the medical field, Branislav saw an opportunity that could have an impact on people’s life.

He saw heart as a source of electromagnetic waves. In essence an antenna! "If we can measure x,y and z components of the signal that this antenna called heart transmits we will have all the information somebody can collect about heart’s electrical activity," he says passionately. He joined with two other physicists and came up with way to detect a heart attack by treating the heart as an antenna!

Branislav had seen the market was crowded with too many players who offered two electrode or single lead based ECG offerings. He was convinced that single lead ECG technologies are by no means sufficient , especially in ischemic events. "The only significant arrhythmia single lead ECG technologies have tackled so far is atrial fibrillation (Afib). What is needed is a technology that will be able to provide disease detection capabilities that are at least as good as the standard 12 lead ECG, but with the patient/user 24/7," says Branislav. It is this space, which is far less populated, that excites him.

What drives him?

There is clearly a dominant motivation factor that drives me: the impact on people’s life. I feel that my work on Flash memory has changed the way we live: mobile phones and digital photography, to name just two would not be possible without Flash. I feel very fortunate that I was in the middle of that technical revolution. HeartBeam will have a huge impact on the lives of cardiovascular patients. My goal is clear: prolong lives and increase the quality of lives of high risk cardiovascular patients.


 February 2020